The holy grail: pan-cancer-targeting T cells

Crowther and Dolton et al. identified an unconventional human T cell clone capable of killing many different types of cancer in vitro in an HLA-independent fashion while sparing healthy cells. Using genome-wide CRISPR-Cas9 screening, the researchers showed that the T cell clone recognized the ubiquitously expressed, mostly monomorphic, MHC-I-related protein MR1 on the surface of cancer cells when MR1 was loaded with a yet unidentified cancer-specific or cancer-associated ligand. Adoptive transfer of this T cell clone into immunodeficient NSG mice with leukemia reduced tumor burden and increased survival.

Cancer immunoediting and resistance to T cell-based immunotherapy

Getting to the heart of complex cancer mutations

Michael G King Jr (@MichaelGKingJr) / X

IJMS, Free Full-Text

Frontiers Effects of the interactions between platelets with

Killing Pancreatic Cancer with T Cells that Supercharge Themselves

Michael G King Jr (@MichaelGKingJr) / X

Our strategy - MYCimmune

Michael G King Jr (@MichaelGKingJr) / X

Discovery of a Pan-Cancer Killing T Cell

Pan-cancer T cell atlas links a cellular stress response state to

IJMS, Free Full-Text

Why T cells - Pan Cancer T

Two cancer research studies reveal essential role of neutrophils in immunotherapy

About Pancreatic Cancer, Penn Pancreatic Cancer Research Center

Uterine Cancer Incidence and Mortality — United States, 1999–2016

Frontiers Cancer, more than a “COVID-19 co-morbidity”

La fatigue liée au cancer - Éditions in Press - Et si on allait mieux !